Cognitive Therapy Plus Antidepressant Improves Depression Symptoms
the Psychiatry Advisor take:
Cognitive therapy (CT) combined with taking an antidepressant leads to better outcomes than taking an antidepressant alone, though the effect appears limited only to patients suffering from severe depression that is not chronic.
Steven D. Hollon, PhD, of the Department of Psychology at Vanderbilt University, Nashville, Tennessee, and colleagues examined 452 adult outpatients with chronic or recurrent major depressive disorder (MDD), who were randomly assigned to antidepressant treatment only or CT combined with an antidepressant. Treatment was administered for up to 42 weeks until recovery.
Combined treatment enhanced the rate of recovery vs. treatment with an antidepressant alone (72.6% vs 62.5%; t451= 2.45; P=0.01; hazard ratio, 1.33; 95% C: 1.06-1.68; number needed to treat, 10; 95% CI: 5-72), the researchers reported in JAMA Psychiatry.
However, those results were conditioned on severity and chronicity of the depression, such that the advantage for combined treatment was limited to patients with severe, nonchronic MDD (81.3% vs. 51.7%; n=146; t145=3.96; P=0.001; HR, 2.34; 95% CI, 1.54-3.57; NNT, 3; 95% CI, 2-5).
Patients with comorbid Axis II disorders took longer to recover than did patients without comorbid Axis II disorders regardless of the condition (P=0.01). Also, patients who received combined treatment reported fewer serious adverse events than did patients who received antidepressants alone (49 vs. 71; P=0.02), largely because they experienced less time in an MDD episode.
Patients' Relationship With Clinician Has Slight Impact on Outcomes
Antidepressant medication (ADM) is efficacious in the treatment of depression, but not all patients achieve remission and fewer still achieve recovery with ADM alone. The objective of the study is to determine the effects of combining cognitive therapy with ADM vs ADM alone on remission and recovery in major depressive disorder.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- FDA Approves Schizophrenia Medication With Digital Ingestion Sensor
- Increased Depression Severity Following Childhood Exposure to Adversity, Risk
- Suboptimal Neuromotor Development Related to Genetic Risk for Schizophrenia
- No Association Between Comorbid Anxiety Disorders, Suicide Attempts
- Cannabidiol Concentration, Labeling Varies Widely in Products Sold Online
- Maintenance rTMS for Treatment-Resistant Depression
- Eye Movement Desensitization and Reprocessing Reduces PTSD Symptoms
- Micronutrients Improve Some Symptoms of ADHD
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse
- Frequent Migraines Increase Severity of Anxiety, Depression
- Abnormal MRI and CSF Findings May Predict Risk for Alzheimer's Dementia
- Genetic Link Between Obesity Traits, Depression With Atypical Features
- Improved Outcomes for Patients Treated by Own PCP During Hospital Stay
- Patients With Excessive Daytime Sleepiness May Benefit From Sodium Oxybate